Frequently Asked Questions about Iovance Biotherapeutics, Inc. (IOVA)

Name: Iovance Biotherapeutics, Inc. (IOVA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Iovance Biotherapeutics, Inc. (IOVA) do?

Accepted Answer

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead pro...

Question 2

Is Iovance Biotherapeutics, Inc. (IOVA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of IOVA reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.26B most recent), help investors decide if IOVA fits their risk profile.

Question 3

What is the current P/E ratio for IOVA?

Accepted Answer

As of the latest trading session, Iovance Biotherapeutics, Inc. (IOVA) has a trailing P/E ratio of N/A.

Question 4

Who is the CEO of Iovance Biotherapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Iovance Biotherapeutics, Inc. is Frederick G. Vogt.

Question 5

What was IOVA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Iovance Biotherapeutics, Inc. reported annual revenues of $0.26B (2025), $0.16B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does IOVA pay a dividend?

Accepted Answer

Iovance Biotherapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does IOVA have?

Accepted Answer

In its latest reporting period, Iovance Biotherapeutics, Inc. generated $-0.34B in Free Cash Flow against a total debt load of $0.05B.

Question 8

What is the Price-to-Book (P/B) ratio of Iovance Biotherapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Iovance Biotherapeutics, Inc. (IOVA) is currently N/A.

Question 9

What is the Price-to-Sales (P/S) ratio of IOVA?

Accepted Answer

Based on trailing twelve-month data, Iovance Biotherapeutics, Inc. (IOVA) trades at a Price-to-Sales (P/S) ratio of N/A.

Question 10

What is Iovance Biotherapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Iovance Biotherapeutics, Inc. (IOVA) has a Return on Equity (ROE) of -54.54%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-302.4M	61.6M	-33.8M	-336.2M	-397.8M
2024-12	-353M	109.6M	-11.1M	-364M	-473.7M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-302.4M	61.6M	-33.8M	-336.2M	-397.8M
2024-12	-353M	109.6M	-11.1M	-364M	-473.7M